Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Beijing Double-Crane Buys Enshi Pharma for $13.7 Million

publication date: Dec 31, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Beijing Double-Crane Pharmaceutical will acquire Shenyang Enshi Pharmaceutical from Enshi Internation for 90 million RMB ($13.7 million). Enshi Pharma produced just 2.4 million RMB of revenue during the first four months of 2010, creating a loss of 3 million RMB. Double-Crane said the acquisition would boost production capacity of its cephalosporin antibiotics. More details....

Stock Symbol: (SHEX: 600062)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners